2024
Disorders due to Substance Use: Stimulants
Sevarino K, Farrell M. Disorders due to Substance Use: Stimulants. 2024, 2843-2932. DOI: 10.1007/978-3-030-51366-5_26.Peer-Reviewed Original ResearchBody of preclinical researchAssociated with significant impairmentStimulant use disorderFDA-approved medicationsBehavioral therapyOccupational functioningUse disorderPrescribed stimulantsSignificant impairmentHepatitis CClinical featuresSubstance usePharmacological therapyMedical illnessPreclinical researchRates of overdose deathsCardiovascular diseaseDisordersElevated ratesElevated riskTherapyPotential targetOverdose deathsStimulationAdverse consequences
2023
Disorders Due to Substance Use: Stimulants
Sevarino K, Farrell M. Disorders Due to Substance Use: Stimulants. 2023, 1-90. DOI: 10.1007/978-3-030-42825-9_26-1.Peer-Reviewed Original ResearchBody of preclinical researchAssociated with significant impairmentStimulant use disorderFDA-approved medicationsBehavioral therapyOccupational functioningUse disorderPrescribed stimulantsSignificant impairmentHepatitis CClinical featuresSubstance usePharmacological therapyMedical illnessPreclinical researchRates of overdose deathsCardiovascular diseaseDisordersElevated ratesElevated riskTherapyPotential targetOverdose deathsStimulationAdverse consequences
2017
Mecamylamine treatment for alcohol dependence: a randomized controlled trial
Petrakis IL, Ralevski E, Gueorguieva R, O'Malley SS, Arias A, Sevarino KA, Jane JS, O'Brien E, Krystal JH. Mecamylamine treatment for alcohol dependence: a randomized controlled trial. Addiction 2017, 113: 6-14. PMID: 28710873, PMCID: PMC5725262, DOI: 10.1111/add.13943.Peer-Reviewed Original ResearchConceptsHeavy drinking daysDrinking daysAlcohol use disorderUse disordersAlcohol consumptionAlcohol dependenceDouble-blind clinical trialNicotinic acetylcholine receptor antagonistWeeks of treatmentAcetylcholine receptor antagonistCurrent alcohol dependenceSignificant differencesTreatment-seeking smokersMecamylamine treatmentPlacebo groupMonth 3Primary outcomeSmoking statusNicotine withdrawalReceptor antagonistNovel pharmacotherapiesClinical trialsManagement therapyMecamylamineTreatment groups
2016
A Randomized Trial of Contingency Management for Smoking Cessation During Intensive Outpatient Alcohol Treatment
Cooney JL, Cooper S, Grant C, Sevarino K, Krishnan-Sarin S, Gutierrez IA, Cooney NL. A Randomized Trial of Contingency Management for Smoking Cessation During Intensive Outpatient Alcohol Treatment. Journal Of Substance Use And Addiction Treatment 2016, 72: 89-96. PMID: 27542442, DOI: 10.1016/j.jsat.2016.07.002.Peer-Reviewed Original ResearchConceptsEnd of treatmentNicotine replacement therapyOutpatient alcohol treatmentContingency managementReplacement therapyDependent smokersQuit ratesAbstinence outcomesAlcohol treatmentEfficacy of CMEvidence-based smoking cessation treatmentOutpatient alcohol treatment programOne monthAlcohol-dependent smokersInitial smoking abstinenceSmoking cessation treatmentDrug use outcomesAlcohol treatment programsCognitive behavioral therapyCognitive behavior therapyCessation treatmentRandomized trialsSmoking cessationSmoking abstinenceClinical trials
2015
Concurrent Alcohol and Tobacco Treatment: Effect on Daily Process Measures of Alcohol Relapse Risk
Cooney NL, Litt MD, Sevarino KA, Levy L, Kranitz LS, Sackler H, Cooney JL. Concurrent Alcohol and Tobacco Treatment: Effect on Daily Process Measures of Alcohol Relapse Risk. Journal Of Consulting And Clinical Psychology 2015, 83: 346-358. PMID: 25622198, PMCID: PMC4380705, DOI: 10.1037/a0038633.Peer-Reviewed Original ResearchConceptsSmoking cessation interventionSmoking treatmentCessation interventionsSmoking abstinenceProcess measuresAlcohol treatmentOutpatient alcohol treatment programAlcohol-dependent smokersDaily smoking abstinenceAlcohol relapse riskOutpatient alcohol treatmentLow alcohol consumptionAlcohol treatment programsDependent smokersRelapse riskAlcohol abstinenceWaiting listInteractive voice response systemSmoking outcomesAlcohol consumptionCSC participantsVoice response systemIVR assessmentsTreatment programDaily assessmentStimulant Use Disorders
Sevarino K, Shelby B. Stimulant Use Disorders. 2015, 1561-1614. DOI: 10.1002/9781118753378.ch80.Peer-Reviewed Original ResearchStimulant use disorderUse disordersMonths of treatmentOngoing psychosocial stressorsSubstance abuse treatmentCocaine use disorderDisease courseAcute cravingAppropriate treatmentHigh riskPsychosocial stressorsAbuse treatmentNonmedical useCrystal methamphetamineDrug abuseDisordersMethamphetamineTreatmentPrescription stimulantsAmphetamineStimulantsPatientsRelapseDextroamphetamineMethylphenidate
2009
Smoking cessation during alcohol treatment: a randomized trial of combination nicotine patch plus nicotine gum
Cooney NL, Cooney JL, Perry BL, Carbone M, Cohen EH, Steinberg HR, Pilkey DT, Sevarino K, Oncken CA, Litt MD. Smoking cessation during alcohol treatment: a randomized trial of combination nicotine patch plus nicotine gum. Addiction 2009, 104: 1588-1596. PMID: 19549054, PMCID: PMC2753831, DOI: 10.1111/j.1360-0443.2009.02624.x.Peer-Reviewed Original ResearchConceptsActive nicotine patchNicotine patchPlacebo gumNicotine gumSmoking cessationDouble-blind placebo-controlled clinical trialAlcohol treatmentPlacebo-controlled clinical trialBetter smoking outcomesCombination nicotine patchTransdermal nicotine patchDouble-blind conditionsSubstance abuse clinicsMonthly booster sessionsCombination nicotine replacementNicotine replacementCessation treatmentTobacco smokersLarge trialsCombination therapyMore cigarettesMedication conditionActive gumClinical trialsBooster sessionsNaltrexone for Initiation and Maintenance of Opiate Abstinence
Sevarino K, Kosten T. Naltrexone for Initiation and Maintenance of Opiate Abstinence. Contemporary Neuroscience 2009, 227-245. DOI: 10.1007/978-1-59745-197-0_12.Peer-Reviewed Original ResearchPartial opioid agonist buprenorphineDistinct pharmacological classesOpiate agonist methadoneRole of naltrexoneOpioid antagonist naltrexoneAntagonist naltrexoneOpiate dependencePharmacological classesOpiate abstinenceAbstinent statePhysical dependenceLong-term maintenanceNaltrexoneOpiatesBuprenorphinePharmacotherapyMethadoneAbstinence
2008
Substance Abuse: Amphetamine Use Disorders
Sevarino K. Substance Abuse: Amphetamine Use Disorders. 2008, 1005-1018. DOI: 10.1002/9780470515167.ch55.Peer-Reviewed Original Research
2005
Efficacy of dose and contingency management procedures in LAAM-maintained cocaine-dependent patients
Oliveto A, Poling J, Sevarino K, Gonsai K, McCance-Katz E, Stine S, Kosten T. Efficacy of dose and contingency management procedures in LAAM-maintained cocaine-dependent patients. Drug And Alcohol Dependence 2005, 79: 157-165. PMID: 16002025, DOI: 10.1016/j.drugalcdep.2005.01.007.Peer-Reviewed Original ResearchConceptsHC groupOpioid useContingency management proceduresCocaine useEfficacy of DoseOverall opioid useOpioid withdrawal symptomsHigh-dose groupLow-dose groupLY groupDrug-free urineCocaine-dependent patientsCocaine-dependent participantsBaseline characteristicsMaintenance doseWithdrawal symptomsClinical trialsCocaine abstinenceOpioidsLAAMUrine samplesHY groupAbstinenceDoseUrine
2004
Management of psychiatric issues in patients with intellectual disability.
Trestman R, Sevarino K, Kelly M. Management of psychiatric issues in patients with intellectual disability. Connecticut Medicine 2004, 68: 495-8. PMID: 15468619.Peer-Reviewed Original ResearchConceptsIntellectual disabilityMost patientsSymptom burdenAbility of psychiatristsEnvironment of careFunctional capacityPsychiatric treatmentPsychiatric issuesSuch careTreatment interestMental illnessMeaningful improvementsService deliveryTraining of staffPatientsPsychiatric residentsCareDisabilityDeliveryPopulationIllness
2003
Tiagabine increases cocaine‐free urines in cocaine‐dependent methadone‐treated patients: results of a randomized pilot study
Gonzalez G, Sevarino K, Sofuoglu M, Poling J, Oliveto A, Gonsai K, George TP, Kosten TR. Tiagabine increases cocaine‐free urines in cocaine‐dependent methadone‐treated patients: results of a randomized pilot study. Addiction 2003, 98: 1625-1632. PMID: 14616189, DOI: 10.1046/j.1360-0443.2003.00544.x.Peer-Reviewed Original ResearchConceptsMethadone-treated patientsCocaine-free urinesUrine drug testsDouble-blind placebo-controlled trialCocaine useVeterans Affairs Connecticut Healthcare SystemPlacebo-controlled trialDrug testsRandomized pilot studyOpiate Withdrawal ScaleStructured Clinical InterviewSelf-reported cocaine useTreatment Research ProgramAddiction Severity IndexGABAergic medicationsActive medicationStudy entrySelf-reported useWithdrawal ScaleTreatment groupsTiagabineTreatment retentionAverage ageClinical InterviewWeek 9Desipramine and contingency management for cocaine and opiate dependence in buprenorphine maintained patients
Kosten T, Oliveto A, Feingold A, Poling J, Sevarino K, McCance-Katz E, Stine S, Gonzalez G, Gonsai K. Desipramine and contingency management for cocaine and opiate dependence in buprenorphine maintained patients. Drug And Alcohol Dependence 2003, 70: 315-325. PMID: 12757969, DOI: 10.1016/s0376-8716(03)00032-2.Peer-Reviewed Original ResearchConceptsCocaine-free urinesContingency managementCocaine useOpioid withdrawal symptomsUrine toxicology resultsDrug-free urineMethadone treatmentPoor prognosisWithdrawal symptomsMethadone maintenancePlasma levelsDependent patientsToxicology resultsTreatment groupsCell trialsCocaine abuseBuprenorphineDesipraminePatientsCocaine abusersOpiatesSymptom levelsUrineAdditive effectCocaineClonidine and yohimbine in opioid-dependent humans responding under a naloxone novel-response discrimination procedure
Oliveto A, Sevarino K, McCance-Katz E, Benios T, Poling J, Feingold A. Clonidine and yohimbine in opioid-dependent humans responding under a naloxone novel-response discrimination procedure. Behavioural Pharmacology 2003, 14: 97-109. PMID: 12658070, DOI: 10.1097/00008877-200303000-00001.Peer-Reviewed Original ResearchConceptsAlpha2-adrenergic antagonist yohimbineNovel-response drug discrimination procedureAlpha2-adrenergic agonist clonidineOpioid-dependent humansPlacebo-appropriate respondingOpioid antagonist naloxoneClonidine-induced changesDose-related increaseEffects of yohimbineDoses of naloxoneDrug discrimination procedureOpioid withdrawalAdrenergic mechanismsAntagonist yohimbineAgonist clonidineAntagonist naloxoneOpioid antagonistClonidineLow doseNaloxoneTraining doseYohimbineDrug conditionsDiscrimination procedureDoseThe Thyrotropin-Releasing Hormone (TRH) Hypothesis of Homeostatic Regulation: Implications for TRH-Based Therapeutics
Gary K, Sevarino K, Yarbrough G, Prange A, Winokur A. The Thyrotropin-Releasing Hormone (TRH) Hypothesis of Homeostatic Regulation: Implications for TRH-Based Therapeutics. Journal Of Pharmacology And Experimental Therapeutics 2003, 305: 410-416. PMID: 12606661, DOI: 10.1124/jpet.102.044040.Peer-Reviewed Original ResearchConceptsThyrotropin-releasing hormoneCentral nervous systemAction of TRHTherapeutic agentsSpinal cord systemsTherapeutic benefitTRH analogNervous systemClinical situationsCNS activityNeuroendocrine systemHormone hypothesisMetabolic homeostasisCortical systemsHuman illnessMyriad actionsHomeostatic regulationNeurobiological functionsDrugsHomeostatic systemGlobal functionManifold actionsChronobiological systemHomeostasisBroad spectrum
2002
Ketoconazole increases cocaine and opioid use in methadone maintained patients
Kosten T, Oliveto A, Sevarino K, Gonsai K, Feingold A. Ketoconazole increases cocaine and opioid use in methadone maintained patients. Drug And Alcohol Dependence 2002, 66: 173-180. PMID: 11906804, DOI: 10.1016/s0376-8716(01)00198-3.Peer-Reviewed Original ResearchConceptsCortisol synthesis inhibitorOpioid usePlacebo treatmentCocaine useDouble-blind trialMorning cortisol levelsStress-induced reinstatementCocaine-related behaviorsSynthesis inhibitorSubstance abuse problemsMethadone treatmentWithdrawal symptomsKetoconazole treatmentPharmacological adrenalectomyClinical trialsBlind trialSide effectsCocaine abuseCortisol levelsMethadoneNormal valuesPatientsSubjective effectsKetoconazoleTreatment implicationsExcitatory glycine receptors containing the NR3 family of NMDA receptor subunits
Chatterton JE, Awobuluyi M, Premkumar LS, Takahashi H, Talantova M, Shin Y, Cui J, Tu S, Sevarino KA, Nakanishi N, Tong G, Lipton SA, Zhang D. Excitatory glycine receptors containing the NR3 family of NMDA receptor subunits. Nature 2002, 415: 793-798. PMID: 11823786, DOI: 10.1038/nature715.Peer-Reviewed Original ResearchMeSH KeywordsAnimalsCalciumCations, DivalentCentral Nervous SystemCloning, MolecularElectrophysiologyGlutamic AcidGlycineImmunohistochemistryIn Situ HybridizationIon TransportMagnesiumMolecular Sequence DataN-MethylaspartateNeuronsOocytesProtein SubunitsRatsReceptors, GlycineReceptors, N-Methyl-D-AspartateRNA, MessengerSequence HomologySerineSubstrate SpecificityXenopus laevisConceptsExcitatory glycine receptorsGlycine receptorsN-methyl-D-aspartate (NMDA) subtypeD-serineCentral nervous systemNMDA receptor subunitsImpermeable cation channelsVoltage-dependent inhibitionBursts of firingMK-801Inhibitory neurotransmitterMotor neuronsGlutamate receptorsCerebrocortical neuronsCompetitive antagonistNervous systemDual agonistsNMDARNMDAR familyReceptor subunitsNeuronal developmentPathological processesCation channelsReceptorsNR3AButorphanol and nalbuphine in opioid-dependent humans under a naloxone discrimination procedure
Oliveto A, Sevarino K, McCance-Katz E, Feingold A. Butorphanol and nalbuphine in opioid-dependent humans under a naloxone discrimination procedure. Pharmacology Biochemistry And Behavior 2002, 71: 85-96. PMID: 11812511, DOI: 10.1016/s0091-3057(01)00637-2.Peer-Reviewed Original ResearchConceptsNaloxone-appropriate respondingOpioid antagonist naloxoneDose-related increaseAntagonist naloxoneNovel-response drug discrimination procedureOpioid agonist/antagonistOpioid-dependent humansDoses of naloxoneDiscriminative stimulus effectsDrug discrimination procedureAgonists/antagonistsAppropriate respondingLow doseHigh doseNaloxoneSelf-reported effectsDiscrimination procedureDrug conditionsHigh dosesNalbuphineButorphanolDosesDoseRespondingPlacebo
2000
Comparison of intravenous cocaethylene and cocaine in humans
Hart C, Jatlow P, Sevarino K, McCance-Katz E. Comparison of intravenous cocaethylene and cocaine in humans. Psychopharmacology 2000, 149: 153-162. PMID: 10805610, DOI: 10.1007/s002139900363.Peer-Reviewed Original ResearchConceptsBlood pressureActive drug conditionsDouble-blind studyDiastolic blood pressureSystolic blood pressureTransesterification of cocaineCocaine-dependent participantsStudy drugMetabolite of cocaineHeart rateSlow clearanceDrug conditionsSeparate daysHuman volunteersSubjective effectsPharmacological propertiesEquivalent dosesCocainePlaceboSignificant increaseSimilar differencesCocaethyleneExperimental sessionsSubjective measuresPrevious studiesNeurobiological Adaptations to Psychostimulants and Opiates as a Basis of Treatment Development
SEVARINO K, OLIVETO A, KOSTEN T. Neurobiological Adaptations to Psychostimulants and Opiates as a Basis of Treatment Development. Annals Of The New York Academy Of Sciences 2000, 909: 51-87. PMID: 10911924, DOI: 10.1111/j.1749-6632.2000.tb06676.x.Peer-Reviewed Original ResearchConceptsOpiate withdrawalLocus coeruleus noradrenergic neuronsWorldwide public health issueTreatment developmentNeurobiological adaptationsCerebral perfusion abnormalitiesTrials of antidepressantsPublic health issueNew treatment developmentCocaine vaccineAntagonist therapyNoradrenergic neuronsHeroin effectsChronic usePerfusion abnormalitiesSerotonin neurotransmissionOpiate dependenceClinical experienceOpiate maintenanceCocaine dependenceBehavioral treatmentOpiate addictionIllicit substancesHealth issuesPsychostimulants